tiprankstipranks
Trending News
More News >
Advertisement
Advertisement

Iovance Biotherapeutics downgraded to Sell from Neutral at Goldman Sachs

Goldman Sachs downgraded Iovance Biotherapeutics (IOVA) to Sell from Neutral with a price target of $1, down from $8. The firm cites the slower than expected launch of the company’s lead drug Amtagvi in second-line melanoma for the downgrade. Key opinion leader discussions and a physician survey indicate underutilization of Amtagvi due to a limited eligible patient population as well as logistical and operational complexities, the analyst tells investors in a research note.

Elevate Your Investing Strategy:

  • Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Disclaimer & DisclosureReport an Issue

1